ZURICH/LONDON, June 7 (Reuters) - Novartis AG (NOVN.VX: Quote, Profile, Research) boosted its infectious diseases portfolio on Wednesday by agreeing to buy British firm NeuTec Pharma Plc (NTP.L: Quote, Profile, Research), a specialist in fighting hospital superbugs, for $569 million.
